Actually, the new direction could well be specific to the collaboration recently announced with Achieve Clinics. The new direction of retrieving blood and its valuable immune cells from patients, before they get ravaged by chemo as the standard of care, is a boon for autologous cell therapies (currently the accepted norm). While allogeneic cell manufacturing has its upsides, there will be a place for personalised / autologous methods due to the former having potential issues due to immune rejection.
The blood bank concept really has a lot of merit for patients, clinicians and doctors. The collab with AC puts CHM within an ecosystem that our team can tap into and where our clinical trials will have greater reach and exposure.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)